After the research of Masui et al. in 1983 that provided evidence on the activity of anti-EGFR drugs against epidermoid carcinoma cell growth in vivo [97], many studies and clinical trials focused on two classes of anti-EFGR agents, which are the anti-EGFR monoclonal antibodies (cetuximab and panitumumab) and the small-molecule EGFR tyrosine kinase inhibitors [92]. The gene discussed is EGFR; the disease is squamous cell carcinoma.